BRPI0924547B1 - Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso - Google Patents

Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso Download PDF

Info

Publication number
BRPI0924547B1
BRPI0924547B1 BRPI0924547-2A BRPI0924547A BRPI0924547B1 BR PI0924547 B1 BRPI0924547 B1 BR PI0924547B1 BR PI0924547 A BRPI0924547 A BR PI0924547A BR PI0924547 B1 BRPI0924547 B1 BR PI0924547B1
Authority
BR
Brazil
Prior art keywords
compound
formula
reaction
phenyl
dimethylbenzyloxy
Prior art date
Application number
BRPI0924547-2A
Other languages
English (en)
Portuguese (pt)
Inventor
James Dennen O´Neil
Michael K. Bamat
Reid W. Von Borstel
Ramachandran Arudchandran
Shalini Sharma
Original Assignee
Wellstat Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corporation filed Critical Wellstat Therapeutics Corporation
Publication of BRPI0924547A2 publication Critical patent/BRPI0924547A2/pt
Publication of BRPI0924547B1 publication Critical patent/BRPI0924547B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/38—Sucrose-free products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A23G3/56—Products with edible or inedible supports, e.g. lollipops
    • A23G3/563—Products with edible or inedible supports, e.g. lollipops products with an inedible support, e.g. a stick
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/716—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
BRPI0924547-2A 2008-03-13 2009-03-13 Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso BRPI0924547B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3629408P 2008-03-13 2008-03-13
US61/036,294 2008-03-13
BRPI0909299-4A BRPI0909299B1 (pt) 2008-03-13 2009-03-13 Compostos e métodos para redução de ácido úrico
PCT/US2009/037128 WO2009151695A1 (en) 2008-03-13 2009-03-13 Compounds and method for reducing uric acid

Publications (2)

Publication Number Publication Date
BRPI0924547A2 BRPI0924547A2 (pt) 2015-06-23
BRPI0924547B1 true BRPI0924547B1 (pt) 2021-08-17

Family

ID=41417026

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0924547-2A BRPI0924547B1 (pt) 2008-03-13 2009-03-13 Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso
BRPI0909299-4A BRPI0909299B1 (pt) 2008-03-13 2009-03-13 Compostos e métodos para redução de ácido úrico

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0909299-4A BRPI0909299B1 (pt) 2008-03-13 2009-03-13 Compostos e métodos para redução de ácido úrico

Country Status (17)

Country Link
US (2) US8829058B2 (https=)
EP (2) EP3517109A1 (https=)
JP (2) JP5339545B2 (https=)
KR (2) KR101677944B1 (https=)
CN (2) CN102976928B (https=)
AU (1) AU2009258040B8 (https=)
BR (2) BRPI0924547B1 (https=)
CA (1) CA2716860C (https=)
DK (1) DK2268141T3 (https=)
ES (1) ES2741153T3 (https=)
IL (2) IL208004A (https=)
MX (2) MX342806B (https=)
NZ (2) NZ602321A (https=)
RU (2) RU2501554C2 (https=)
UA (2) UA109638C2 (https=)
WO (1) WO2009151695A1 (https=)
ZA (1) ZA201005872B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109638C2 (uk) 2008-03-13 2015-09-25 Сполуки та спосіб зниження рівня сечової кислоти
NZ588374A (en) 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
CN102573462B (zh) * 2009-10-13 2014-04-16 维尔斯达医疗公司 用于降低尿酸的3位取代的化合物
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
DK2669270T3 (en) 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
US20140142185A1 (en) * 2011-03-14 2014-05-22 Shalini Sharma 3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
WO2013155478A1 (en) * 2012-04-13 2013-10-17 Metabolex, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
WO2014017643A1 (ja) 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
US11000492B2 (en) 2015-11-13 2021-05-11 The Trustees Of Columbia University In The City Of New York Fluorenone compound for the treatment of gout
US12057228B1 (en) * 2015-12-30 2024-08-06 Cerner Innovation, Inc. Predicting newly incident chronic kidney disease
CN106190954B (zh) * 2016-07-25 2019-12-10 华南理工大学 一种高尿酸血症肝细胞模型及其构建方法
CN106190953B (zh) * 2016-07-25 2019-12-10 华南理工大学 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用
KR101988867B1 (ko) 2017-07-25 2019-06-13 광주과학기술원 금 나노입자를 이용한 요산 분해용 조성물
WO2019066469A1 (ko) * 2017-09-27 2019-04-04 경북대학교 산학협력단 페북소스타트 또는 토피록소스타트의 암 전이의 예방 및 치료제로서의 용도
KR102836208B1 (ko) * 2020-03-27 2025-07-18 가톨릭대학교 산학협력단 통풍 동반 관절염 모델 평가 플랫폼
WO2021194294A1 (ko) * 2020-03-27 2021-09-30 가톨릭대학교 산학협력단 자가면역질환 평가 아바타 모델 플랫폼

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572512B1 (fr) 1984-10-25 1987-09-25 Luchaire Sa Dispositif, adaptable sur engins ou munitions, tels que projectiles d'artillerie, destine a reduire leur trainee de culot
DE3884825D1 (de) 1987-02-16 1993-11-18 Konishiroku Photo Ind Entwickler für lichtempfindliche lithographische Druckplatte, gemeinschaftlich verarbeitungsfähig für den Negativ-Typ und den Positiv-Typ und Entwicklerzusammensetzung für lichtempfindliches Material.
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
AU4953796A (en) 1995-03-15 1996-10-02 Sanyko Company, Limited Dipeptide compounds having ahpba structure
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
CN101444496B (zh) * 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
EP1556085A4 (en) * 2002-11-01 2012-08-22 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM
CN1750758B (zh) 2003-02-13 2012-06-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
RU2358722C2 (ru) * 2003-04-15 2009-06-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических расстройств
JP4837557B2 (ja) 2003-04-30 2011-12-14 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
TWI280136B (en) * 2003-05-30 2007-05-01 Lytone Enterprise Inc Composition containing dipeptide of histidine and alanine for reducing uric acid
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
US7494537B2 (en) * 2004-11-15 2009-02-24 The Pilot Ink Co., Ltd. Thermochromic coloring color-memory composition and thermochromic coloring color-memory microcapsule pigment containing the same
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
UA95613C2 (ru) 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
JP2009528275A (ja) 2006-01-25 2009-08-06 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
EP2026659A4 (en) 2006-06-09 2010-06-30 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
WO2008022267A2 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
EP2240024A4 (en) 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
UA109638C2 (uk) 2008-03-13 2015-09-25 Сполуки та спосіб зниження рівня сечової кислоти
NZ588374A (en) 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid

Also Published As

Publication number Publication date
BRPI0909299A2 (pt) 2014-02-04
KR101677945B1 (ko) 2016-11-29
BRPI0909299B1 (pt) 2021-11-23
UA103894C2 (ru) 2013-12-10
EP3517109A1 (en) 2019-07-31
JP5547222B2 (ja) 2014-07-09
WO2009151695A4 (en) 2010-03-04
MX2010009959A (es) 2010-10-04
AU2009258040B8 (en) 2014-04-24
CA2716860A1 (en) 2009-12-17
EP2268141A4 (en) 2011-09-14
BRPI0924547A2 (pt) 2015-06-23
CA2716860C (en) 2017-08-29
RU2012110592A (ru) 2013-09-27
RU2010141823A (ru) 2012-04-20
ES2741153T3 (es) 2020-02-10
EP2268141B1 (en) 2019-05-08
RU2501554C2 (ru) 2013-12-20
NZ602321A (en) 2013-02-22
AU2009258040B2 (en) 2014-02-20
US9115072B2 (en) 2015-08-25
UA109638C2 (uk) 2015-09-25
CN101969773A (zh) 2011-02-09
JP2011515349A (ja) 2011-05-19
KR20100127250A (ko) 2010-12-03
US20110014176A1 (en) 2011-01-20
JP5339545B2 (ja) 2013-11-13
AU2009258040A8 (en) 2014-04-24
WO2009151695A1 (en) 2009-12-17
IL208004A (en) 2016-08-31
US8829058B2 (en) 2014-09-09
KR101677944B1 (ko) 2016-11-21
CN102976928A (zh) 2013-03-20
AU2009258040A1 (en) 2009-12-17
EP2268141A1 (en) 2011-01-05
IL208004A0 (en) 2010-12-30
NZ587433A (en) 2012-12-21
US20130259850A1 (en) 2013-10-03
RU2501555C2 (ru) 2013-12-20
MX342806B (es) 2016-10-13
DK2268141T3 (da) 2019-07-29
IL247136B (en) 2018-06-28
JP2012153690A (ja) 2012-08-16
CN101969773B (zh) 2015-08-19
ZA201005872B (en) 2011-05-25
CN102976928B (zh) 2014-09-17
KR20140119149A (ko) 2014-10-08

Similar Documents

Publication Publication Date Title
BRPI0924547B1 (pt) Composto ácido 2-(3-(2,6-dimetilbenzilóxi)-4-metilfenil)acético, sua composição, bem como seu uso
RU2522458C2 (ru) Тетразольные соединения для снижения концентрации мочевой кислоты
US10085957B2 (en) Benzoic acid compounds for reducing uric acid
EP2266946A2 (en) Compound For The Treatment Of Metabolic Disorders
JP2018526417A (ja) 高尿酸血症又は痛風の治療又は予防用化合物
WO2012125533A1 (en) 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
AU2013200226B2 (en) Compounds and method for reducing uric acid
HK40011494A (en) Compounds and method for reducing uric acid
JP5496913B2 (ja) 代謝異常の治療のための化合物
HK1147647A (en) Compounds and method for reducing uric acid
HK1147647B (en) Compounds and method for reducing uric acid
WO2007060976A1 (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/08

Ipc: A61K 31/192 (2006.01), A61K 31/216 (2006.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: EXTINCAO DA PATENTE POR FALTA DE PAGAMENTO DA 14A RETRIBUICAO ANUAL, POR PAGAMENTO DA RETRIBUICAO ANUAL FORA DO PRAZO OU POR NAO CUMPRIMENTO DE EXIGENCIA DE COMPLEMENTACAO DE PAGAMENTO DA RETRIBUICAO ANUA

B24D Patent annual fee: restoration after fee payment
B25G Requested change of headquarter approved

Owner name: WELLSTAT THERAPEUTICS CORPORATION (US)

B25A Requested transfer of rights approved

Owner name: PHARMA CINQ, LLC (US)